Form 4: Myriad Genetics Director Heinrich Dreismann Boosts Stake with 49,796 RSU Grant

Myriad Genetics Inc. Director Heinrich Dreismann has increased his beneficial ownership by 49,796 shares of common stock through a restricted stock unit grant, bringing his total holdings to 171,444 shares.

Summary

• Heinrich Dreismann, a Director of Myriad Genetics Inc. (MYGN), acquired 49,796 shares of common stock on June 5, 2025.
• The acquisition was a grant of restricted stock units (RSUs) at a price of $0 per share, issued under Myriad Genetics, Inc.'s 2017 Employee, Director and Consultant Equity Incentive Plan.
• Each RSU represents a contingent right to receive one share of common stock.
• Following this transaction, Mr. Dreismann's total beneficial ownership in Myriad Genetics common stock stands at 171,444 shares.
• The granted RSUs are set to vest upon the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders following the grant.

Sentiment

Score: 7

Explanation: The acquisition of shares by a director, even through a grant, is generally a positive signal as it increases insider ownership and aligns management's interests with shareholders. While not an open market purchase, it still represents a commitment to the company's future.

Positives

• A director's acquisition of shares, even through a grant, aligns their interests with those of shareholders, indicating confidence in the company's future.
• The grant of restricted stock units is a common form of equity compensation, incentivizing long-term commitment and performance from directors.
• The increase in beneficial ownership by a director strengthens insider holdings.

Negatives

• The acquisition was a grant at $0, not an open market purchase, meaning the director did not use personal capital to buy shares at market price.

Future Outlook

The vesting schedule of the restricted stock units indicates a future commitment from the director, aligning their interests with the company's long-term performance. The shares will vest upon the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders following the grant.

Industry Context

This Form 4 filing details an insider transaction, specifically an equity grant to a director. Such grants are standard practice in the biotechnology and diagnostics industry, including companies like Myriad Genetics, to attract and retain executive talent and align their interests with long-term shareholder value. It does not provide broader industry trends or competitive analysis.

Comparison to Industry Standards

• The grant of restricted stock units (RSUs) to directors is a common compensation practice across publicly traded companies, particularly in the biotech and healthcare sectors.
• Companies such as Illumina (ILMN), Exact Sciences (EXAS), and Guardant Health (GH) also utilize equity-based compensation plans, including RSU grants, to incentivize their leadership.
• The specific vesting terms (earlier of one year or next annual meeting) are also typical for director equity awards, aiming to ensure continued engagement and alignment with shareholder interests over a reasonable period.

Corporate Governance

Related Party Transactions

• The grant of restricted stock units to Heinrich Dreismann, a director, constitutes a related party transaction as it involves compensation from the company to a member of its board.

Stakeholder Impact

• Shareholders: Increased alignment of director's interests with shareholders due to increased beneficial ownership.
• Employees/Consultants: The grant is part of a broader equity incentive plan, which can positively impact morale and retention for other plan participants.

Next Steps

• The restricted stock units will vest upon the earlier of the first anniversary of the grant date (June 5, 2026) or the date of the next annual meeting of stockholders following the grant.

Key Dates

Recommendation

Keywords

Myriad Genetics, MYGN, Heinrich Dreismann, Form 4, SEC filing, Insider transaction, Restricted Stock Units, RSU grant, Director compensation, Equity incentive plan, Beneficial ownership, Common stock